Mayo made a good call, no doubt.
I don't know how a brief, 28 day Phase 2 safety and tolerability schizophrenia trial could expect to demonstrate efficacy for an upstream S1R drug like 3-71. If blarcamesine's AD experience is any guide, which I think it is, most downstream cognitive clinical effects for 3-71 will be seen more than six months into the trial.
Designing a safety and tolerability schizo trial to last about a year would have been a waste of time and money just to meet an exploratory efficacy endpoint.
Market Data 
Markets 
AI
